key: cord-0848759-xxtgzo5e
authors: Gagne, Matthew; Moliva, Juan I.; Foulds, Kathryn E.; Andrew, Shayne F.; Flynn, Barbara J.; Werner, Anne P.; Wagner, Danielle A.; Teng, I-Ting; Lin, Bob C.; Moore, Christopher; Jean-Baptiste, Nazaire; Carroll, Robin; Foster, Stephanie L.; Patel, Mit; Ellis, Madison; Edara, Venkata-Viswanadh; Maldonado, Nahara Vargas; Minai, Mahnaz; McCormick, Lauren; Honeycutt, Christopher Cole; Nagata, Bianca M.; Bock, Kevin W.; Dulan, Caitlyn N. M.; Cordon, Jamilet; Todd, John-Paul M.; McCarthy, Elizabeth; Pessaint, Laurent; Van Ry, Alex; Narvaez, Brandon; Valentin, Daniel; Cook, Anthony; Dodson, Alan; Steingrebe, Katelyn; Flebbe, Dillon R.; Nurmukhambetova, Saule T.; Godbole, Sucheta; Henry, Amy R.; Laboune, Farida; Roberts-Torres, Jesmine; Lorang, Cynthia G.; Amin, Shivani; Trost, Jessica; Naisan, Mursal; Basappa, Manjula; Willis, Jacquelyn; Wang, Lingshu; Shi, Wei; Doria-Rose, Nicole A.; Olia, Adam S.; Liu, Cuiping; Harris, Darcy R.; Carfi, Andrea; Mascola, John R.; Kwong, Peter D.; Edwards, Darin K.; Andersen, Hanne; Lewis, Mark G.; Corbett, Kizzmekia S.; Nason, Martha C.; McDermott, Adrian B.; Suthar, Mehul S.; Moore, Ian N.; Roederer, Mario; Sullivan, Nancy J.; Douek, Daniel C.; Seder, Robert A.
title: mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
date: 2022-02-04
journal: bioRxiv
DOI: 10.1101/2022.02.03.479037
sha: 09b6dc790e0d408fd7db8da693ec5fa4ecba2f46
doc_id: 848759
cord_uid: xxtgzo5e

SARS-CoV-2 Omicron is highly transmissible and has substantial resistance to antibody neutralization following immunization with ancestral spike-matched vaccines. It is unclear whether boosting with Omicron-specific vaccines would enhance immunity and protection. Here, nonhuman primates that received mRNA-1273 at weeks 0 and 4 were boosted at week 41 with mRNA-1273 or mRNA-Omicron. Neutralizing antibody titers against D614G were 4760 and 270 reciprocal ID50 at week 6 (peak) and week 41 (pre-boost), respectively, and 320 and 110 for Omicron. Two weeks after boost, titers against D614G and Omicron increased to 5360 and 2980, respectively, for mRNA-1273 and 2670 and 1930 for mRNA-Omicron. Following either boost, 70-80% of spike-specific B cells were cross-reactive against both WA1 and Omicron. Significant and equivalent control of virus replication in lower airways was observed following either boost. Therefore, an Omicron boost may not provide greater immunity or protection compared to a boost with the current mRNA-1273 vaccine.

The COVID-19 mRNA vaccines BNT162b2 and mRNA-1273 provide highly effective 20 protection against symptomatic and severe infection with ancestral SARS-CoV-2 (Baden et al., 21 2021b; Dagan et al., 2021; Pilishvili et al., 2021; Polack et al., 2020) . More recently, protective 22 efficacy has declined due to both waning vaccine-elicited immunity (Baden et al., 2021a; 23 Bergwerk et al., 2021; Goldberg et al., 2021) and antigenic shifts in variants of concern (VOC) 24 including B.1.351 (Beta) and B.1.617.2 (Delta) (Planas et al., 2021; Wang et al., 2021a; Wang et 25 al., 2021b) . Importantly, the introduction of a boost after the initial vaccine regimen enhances 26 immunity and vaccine efficacy against symptomatic disease, hospitalization and death across a 27 broad range of age groups (Andrews et al., 2022; Bar-On et al., 2021; Barda et al., 2021; Garcia-28 Beltran et al., 2022; Pajon et al., 2022) . However, the timing and selection of a boost is a major 29 scientific and clinical challenge during this evolving pandemic in which emerging VOC have 30 distinctive patterns of transmission and virulence and against which vaccine-elicited antibody 31 neutralization is reduced. 32

The most recent VOC, B.1.1.529, henceforth referred to by its WHO designation of Omicron, 34 was first identified in South Africa in November 2021 and was associated with a dramatic 35 increase in COVID-19 cases (Cele et al., 2021; Maslo et al., 2021) . Omicron is highly 36 contagious, with a significant transmission advantage compared to Delta, which until recently 37 was the dominant VOC worldwide (Viana et al., 2022) . It remains unclear, however, if this 38 advantage is due to differences in cell entry, enrichment in respiratory aerosols, or the ability to 39 evade immunity conferred by vaccination or prior infection. Compared to the ancestral strain, 40

Omicron contains more than 30 mutations in the spike (S) gene, including S477N, T478K, 41 E484A, Q493R, G496S, Q498R, N501Y and Y505H in the receptor binding motif (RBM) alone. 42

Neutralizing antibody titers in sera of individuals recently recovered from previous infection or 43

shortly after immunization with two doses of an mRNA-based COVID-19 vaccine are 44 dramatically reduced to Omicron as compared to the ancestral strains Wuhan-Hu-1, USA-45 WA1/2020 (WA1) and D614G. Numerous studies using both live virus and pseudovirus 46 neutralization assays report a 60-to 80-fold reduction for convalescent sera and a 20-to 130-fold 47 reduction for vaccinee sera (Edara et al., 2021a; Hoffmann et al., 2021; Muik et al., 2022; 48 Schmidt et al., 2021) . mRNA-1273 vaccine efficacy against breakthrough cases of Omicron in 49 the first few months after immunization has been estimated as 30% in California, USA and 37% 50 in Denmark (Hansen et al., 2021; Tseng et al., 2022) and a complete loss of protection within six 51 months (Accorsi et al., 2022) . Multiple reports have suggested that Omicron has reduced 52 virulence compared to prior VOC in humans, mice and hamsters (Davies et al., 2022; Halfmann 53 et al., 2022; Suryawanshi et al., 2022) . It is possible that reduced virulence of Omicron may 54 result from preferential replication in the upper airway compared to the lungs, perhaps due to 55 altered cellular tropism not reliant on expression of transmembrane serine protease 2 56 (TMPRSS2) (Meng et al., 2022; Willett et al., 2022) . However, the effect of any reduction in 57 intrinsic viral pathogenicity may be somewhat offset in the context of reduced vaccine efficacy 58 and enhanced virus transmission in human populations worldwide. Together these data reinforce 59 the value of boosting to limit the extent of infection from Omicron. 60 61 Variant-matched boosts have been suggested as a strategy to enhance neutralizing and binding 62 antibody titers to the corresponding VOC beyond the levels conferred by existing FDA-approved 63 boosts, which are homologous to the original ancestral WA1-matched primary vaccine regimen. 64

We previously showed that boosting mRNA-1273 immunized nonhuman primates (NHP) with 65 mRNA-1273 or a boost matched to the Beta VOC spike (mRNA-1273.351 or mRNA-1273.Beta) 66 resulted in significant enhancement of neutralizing antibody responses across all VOC tested and 67 an expansion of S-specific memory B cells with ~80-90% expressing WA1 and Beta. Moreover, 68 both vaccines provided substantial and similar protection against Beta replication (Corbett et al., 69 2021a) . These NHP data were confirmed in a study in humans which compared an mRNA -1273 70 boost to mRNA-1273.Beta ~6 months after participants had received the standard two-dose 71 mRNA-1273 vaccine regimen (Choi et al., 2021) . Following either boost, neutralizing titers were 72 substantially increased against D614G and several variants including Beta and were comparable 73 between boost groups. Of note, the level of neutralizing antibodies to Beta after either boost were 74 about 10-fold higher than after the initial vaccination suggesting affinity maturation or epitope 75

focusing of the B cell response. Together, these data suggest that the variant Beta boost did not 76 uniquely enhance immunity or protection compared to existing ancestral strain-matched boosts. 77

However, as Omicron contains more mutations in S compared to Beta and demonstrates even 78 more substantial escape from vaccine-elicited neutralizing antibodies than does Beta, it is unclear 79

whether an Omicron-specific boost would provide an additional protective benefit against 80

Omicron infection beyond that of WA1-matched boosts. 81

The nonhuman primate (NHP) model has been useful for demonstrating immune correlates, 83 mechanisms and durability of vaccine-elicited protection against SARS-CoV-2 and been largely 84 predictive for what has been observed in humans in terms of protective efficacy (Corbett et al., 85 2021b; Gagne et al., 2022; Gilbert et al., 2021) . Here, we vaccinated NHP with 100µg mRNA-86 1273 at weeks 0 and 4, which is a similar dose and schedule as used in humans. Animals were 87 then boosted about ~9 months later with 50µg of either a homologous dose of mRNA-1273 or 88 mRNA-1273.529, which is matched to Omicron S (henceforth referred to as mRNA-Omicron). 89

For the duration of these 9 months, we collected sera, bronchoalveolar lavage (BAL) and nasal 90 washes to analyze the kinetics of antibody binding and neutralization as well as the frequency of 91 S-specific B cells for WA1 and Omicron as well as Beta and Delta. Four weeks after boost, NHP 92 were challenged with Omicron. Viral replication in upper and lower airways and lung 93 inflammation were measured to compare boost-elicited protection against Omicron. 94 95

Kinetics of serum antibody responses following mRNA-1273 immunization and boost 97

Indian-origin rhesus macaques (n=8) were immunized with 100µg of mRNA-1273 at weeks 0 98 and 4 (Fig. S1 ). Sera were collected at weeks 6 (peak) and 41 (memory) to measure 99 immunoglobulin G (IgG) binding to WA1 S and a panel of VOC (Fig. 1A) . At week 6, we 100 observed a clear hierarchy of binding titers with WA1>Delta>Beta >Omicron. Geometric mean 101 titers (GMT) to WA1 and Omicron were 8x10 19 and 3x10 15 area under the curve (AUC). 102 Antibody titers waned markedly by week 41, with GMT of 2x10 12 and 2x10 8 AUC for WA1 and 103

Omicron, reflecting a 7-log decline for each strain. Similar antibody kinetics and hierarchy of 104 potency were observed when measuring binding to the receptor binding domain (RBD) of the 105 same variants, with titers to Omicron of 7x10 11 AUC at week 6 and 8x10 7 AUC at week 41 ( Fig.  106 1B). Nine months after the second dose of mRNA-1273 (week 41), NHP were boosted with 107 50µg of homologous mRNA-1273 or heterologous virus challenge-matched mRNA-Omicron 108 (n=4/group). S-binding titers were restored to the same level as observed at week 6 following 109 either a homologous or heterologous boost, and titers to Omicron were still lower than all other 110 variants. 111 112 Neutralizing antibody titers were then assessed using a live virus assay ( Fig. 1C and Table S1 ). 113

At week 6, neutralizing titers were highest to D614G followed by Delta, then Beta and Omicron. 114 Titers to all variants markedly declined by week 41, including a drop in reciprocal 50% 115 inhibitory dilution (ID50) titers for D614G from 5560 at week 6 to 330 at week 41 and for 116

Omicron from 110 at week 6 to 33 at week 41. However, following either boost, neutralizing 117 titers to D614G and Delta were increased similar to week 6 and titers to Beta and Omicron were 118 greater than they had been at week 6 (Beta: P=0.05 and 0.035; Omicron: P=0.041 and 0.01 for 119 mRNA-1273 and mRNA-Omicron, respectively). We substantiated these findings using a 120 lentiviral pseudovirus neutralization assay similar to the one used to assess immune responses in 121 human clinical trials (Fig. 1D ). Following either boost, pseudovirus neutralizing titers were 122 greater to Beta and Omicron than they had been at the week 6 time-point, including an increase 123 in Omicron titers from 320 GMT to 2980 GMT in the mRNA- 1273 boost group and 1930 GMT 124 in the mRNA-Omicron boost group (Beta: P=0.022 and <0.0001; Omicron: P=0.049 and 0.002 125 for mRNA-1273 and mRNA-Omicron, respectively). 126

The increase in neutralizing titers to all VOC tested after the third dose could suggest continued 128

Collectively, these data show that boosting with the homologous mRNA-1273 or mRNA-136

Omicron leads to comparable and significant increases in neutralizing antibody responses against 137 all VOC including Omicron. 138 139 mRNA-1273 and mRNA-Omicron boosting increase mucosal antibody responses to Omicron 140

Upper and lower airway antibody response are critical for mediating protection against SARS-141

CoV-2 and were assessed following immunization. Nasal washes (NW) and bronchoalveolar 142 lavage fluid (BAL) were collected at weeks 8 (four weeks after the initial mRNA-1273 143 immunizations), 39 (pre-boost) and 43 (two weeks after the boost). At all timepoints, BAL and 144 NW IgG S-binding titers followed the hierarchy of WA1>Delta>Beta>Omicron ( Fig. 2A-B ), the 145 same trend detected in our serological assays. In BAL, immediately prior to the boost, GMT 146 were 6.8x10 6 , 4.0x10 6 , 1.3x10 6 and 2.5x10 4 AUC for WA1, Delta, Beta and Omicron, 147 respectively. These titers correlated with a 2-fold reduction for Delta compared to WA1, a 5-fold 148 reduction for Beta, and a 275-fold reduction for Omicron. Following either boost, titers were 149 increased by 3-4 logs for all variants. In NW, titers decreased from ~10 11 for WA1, Delta and 150

Beta at week 8 to 1.3x10 6 , 3.7x10 5 and 1.9x10 5 for WA1, Delta and Beta, respectively. GMT to 151

Omicron similarly declined from 8.8x10 8 to 8.7x10 3 AUC and were lower than WA1 and all 152 other variants. Consistent with the findings in the BAL, either boost increased nasal antibody 153 titers ~6-7 logs, with GMT of ~10 12 for WA1, Delta and Beta and ~10 10 for Omicron. 154

In a number of prior NHP studies, we have not been able to detect antibody neutralizing titers 156 using pseudo-or live-virus assays from NW or BAL. However, based on its high sensitivity, we 157 have used the angiotensin converting enzyme 2 receptor (ACE2) inhibition assay to measure 158 antibody function as a surrogate for neutralization capacity (Corbett et al., 2021a; Gagne et al., 159 2022) . While the antigen for determination of binding titers was wildtype S, our ACE2 inhibition 160 assay used stabilized S-2P (Table S2 ). In the BAL, 25-50% median binding inhibition was 161 observed for all variants at week 8, except for Omicron S-2P in which binding inhibition was 162 low to undetectable (Fig. 2C ). ACE2 binding inhibition declined to a median of <15% for all 163 variants by week 39 and then increased after either the homologous or mRNA-Omicron boost to 164 levels above those at week 8. Of note, although ACE2 inhibition of Omicron S-2P increased 165 following the boost, it remained lower than all other variants. In the upper airway, ACE2 166 inhibition was low to undetectable at week 39 following the initial vaccine regimen for all 167 variants. However, after either boost, there was an increase across all variants including Omicron 168 to values higher than the initial peak at week 8 (Fig. 2D) . Thus, boosting with either vaccine was 169 important for enhancing mucosal antibody binding and neutralization responses. The observation of rapid and significant increases in binding and neutralizing antibody titers to 173

Omicron in both blood and mucosal sites after homologous or heterologous mRNA boost 174 suggests an anamnestic response involving the mobilization of cross-reactive memory B cells. 175

Thus, we measured B cell binding to pairs of fluorochrome-labeled S-2P probes with different 176 VOC including Omicron at weeks 6, 41 and 43 (2 weeks post-boost) (Fig. S2 ). Of the total S-2P 177 specific memory B cell responses at week 6, 63% were dual-specific and capable of binding both 178 WA1 and Omicron probes, with 33% binding WA1 alone and only 4% which bound Omicron 179 alone (Fig. 3A, 4A ). By week 41, the total S-specific memory B cell compartment had declined 180 ~90% as a fraction of all class-switched memory B cells (Fig. S3A ), although the dual-specific 181 population remained the largest fraction within the S-binding pool (Fig. 4A) . 182 183 Two weeks after boosting, there was an expansion of the total S-specific memory B cell 184 compartment similar to that observed at week 6. Following an mRNA-1273 boost, 24% of all S-185 2P-specific memory B cells were specific for WA1 alone and 71% were dual-specific for WA1 186 and Omicron. After the mRNA-Omicron boost, 81% were dual-specific for WA1 and Omicron., 187 with 12% specific for WA1 only (Fig. 4A ). Of note, we did not observe a population of 188

Omicron-only memory B cells before or after the boost that was clearly distinct from background 189 staining (Fig. 3A) . These data suggest a marked expansion of cross-reactive dual-specific WA1- Omicron elicited serum antibody reactivity with similar RBD specificities ( Fig S4) . It has recently been shown that individuals in South Africa with or without prior vaccination had 203 increased neutralizing antibody titers to Delta and Omicron following Omicron infection (Khan 204 et al., 2022) . Thus, we determined whether there was cross-reactivity of B cells for Delta and 205

Omicron following vaccination. Indeed, 68% of all Delta S-2P and/or Omicron S-2P memory B 206 cells were also dual-specific at week 6 and the remainder of S-binding memory B cells largely 207 bound Delta alone (Fig. 3B, 4B ). Following a third dose, the frequency of dual-specific cells 208 increased to 76% for mRNA-1273 and 85% for mRNA-Omicron, consistent with our findings on 209 cross-reactive B cells using WA1 and Omicron S-2P probes. 210

To complete the analysis and demonstrate cross-reactivity of B cells across other variants, we 212 assessed the frequencies of memory B cells specific for WA-1 and Delta or Beta. We have 213 previously reported that dual-specific WA1 S-2P and Delta S-2P memory B cells accounted for 214 greater than 85% of all memory B cells which bound either spike after two immunizations with 215 mRNA-1273 (Gagne et al., 2022) . Here we confirmed and extended these findings and show that 216 after either boost, ~95% of all WA1-and/or Delta-binding memory B cells are dual-specific ( Fig.  217 3C, 4C). Similar findings were obtained with WA1 and Beta S-2P probes, in which the dual-218 specific population was 85% at week 6 and 90% following either boost (Fig. 3D, 4D ). Of note 219

following the mRNA-Omicron boost, very few B cells were detected that only bound WA1 220 epitopes when co-staining for Delta or Beta. Overall, the data show that cross-reactive cells were 221 expanded following a boost with either mRNA-1273 or mRNA-Omicron while only mRNA-222 1273 was capable of boosting memory B cells specific for WA1 alone (Fig. S3) . 223

We have previously shown that mRNA-1273 immunization elicits TH1, TFH and a low frequency 226 of CD8 responses to S peptides in NHP (Corbett et al., 2020; Corbett et al., 2021a; Corbett et al., 227 2021c; Gagne et al., 2022; Jackson et al., 2020) . Consistent with the prior studies we show that 228 mRNA-1273 elicits TH1, TFH and low-level CD8 T cell responses at the peak of the response 229 (week 6) that decline over time ( Fig. S5 and S6). Boosting with either mRNA-1273 or mRNA-230

Omicron increased TFH responses which could be important for expanding the S-specific 231 memory B cell population following the boost (Johnston et al., 2009; Nurieva et al., 2009; 232 Tangye et al., 2002) . We also detected TH1 and CD8 T cells in BAL at week 8 that decreased to 233 undetectable levels at week 39. Such responses were increased with either mRNA-1273 or In the nose, sgRNA_N copy numbers at days 1 to 4 were low for most animals and were not 260 different between the control and vaccinated cohorts, so protection following vaccination could 261 not be determined ( Fig. 5B ). At day 4, 5/8 controls had detectable virus in the nose as compared 262 to 3/8 vaccinated NHP, with no clear difference between the boost cohorts. However, by day 8, 263 4/8 controls still had detectable sgRNA_N including 2 animals with increased copy numbers 264 while none of the vaccinated NHP had detectable sgRNA. 265

In assessing sgRNA_N in the throat, it is noteworthy that 2 days after challenge, only 1/8 267 vaccinated NHP (in either boost group) had detectable virus in the throat compared to 6/8 control 268 NHP (Fig. 5C) . 269

We also measured the amount of culturable virus using a tissue culture infectious dose assay 271 (TCID50). No virus was detected in the BAL of any vaccinated NHP, while 8/8 and 7/8 control 272 NHP had detectable virus 2 and 4 days after challenge, respectively (Fig. 5D ). In the NS, 1/8 273 boosted animals had culturable virus at any timepoint. In the unvaccinated control animals, 2/8 274 and 3/8 NHP had culturable virus in the nose 2 and 4 days after challenge, respectively (Fig. 5E) . Animals from both boost groups displayed histopathologic alterations that were classified as 285 minimal to mild or moderate. Inflammation was largely characterized by mild and patchy 286 expansion of alveolar capillaries, generalized alveolar capillary hypercellularity, mild and 287 regional type II pneumocyte hyperplasia and, less frequently, scattered collections of immune 288 cells within some alveolar spaces. In contrast, unvaccinated animals were characterized as 289 having a moderate to severe pathology. Lung sections from controls included features 290 characterized by moderate and often diffuse alveolar capillary expansion, diffuse 291 hypercellularity, moderate type II pneumocyte hyperplasia and multiple areas of perivascular 292 cellular infiltration. Together, these data indicate that protection against Omicron was robust in 293 the lungs regardless of boost selection. 294 295

Omicron has become the dominant global variant of SARS-CoV-2 due to its transmission 297 advantage relative to Delta and its ability to evade prior immunity (Grabowski et al., 2022; Viana 298 et al., 2022) . Vaccine efficacy against infection with Omicron has declined and boosting with a 299 third dose of an mRNA COVID-19 vaccine matched to the prototype strain has been shown to 300 restore immunity and protection (Accorsi et al., 2022; Garcia-Beltran et al., 2022; Hansen et al., 301 2021; Pajon et al., 2022; Tseng et al., 2022) . Here, we immunized NHP with 2 doses of mRNA-302 1273 (100µg) and boosted them ~9 months later with 50µg of either mRNA-1273 or mRNA-303

Omicron prior to challenge with Omicron virus. The principal findings were: (1) 9 months after 304 the two-dose regimen, neutralizing and binding antibody titers to Omicron had declined 305 substantially in blood and mucosal airways; (2) after the boost, neutralizing antibody titers to 306 ancestral strains were restored and those to Omicron were increased compared to the peak 307 response after the initial prime and boost; (3) both boosts expanded cross-reactive memory B 308 cells but only the homologous boost was capable of expanding B cells specific for epitopes 309 unique to the ancestral strain; and (4) 1273.Beta 1-2 months after immunization with 2 doses of mRNA-1273 (Corbett et al., 2021a) . In 317 contrast to the lower airway, there were no clear and consistent differences in sgRNA_N copy 318 number at days 2 or 4 in the upper airway of vaccinated or control NHP. Of note, more of the 319 control animals had detectable sgRNA at day 4 and increased sgRNA at day 8 as compared to 320 the boosted animals. We would also note that the amount of Omicron replication as assessed by 321 sgRNA or culturable virus in the control animals is demonstrably different than in our prior 322 studies in which NHP were challenged with WA1, Delta or Beta (Corbett et al., 2020; Corbett et 323 al., 2021c; Gagne et al., 2022) . These findings compliment a growing body of evidence for 324 reduced overall severity of Omicron infection in animal models of COVID-19 compared to other 325 variants (Bentley et al., 2021; Halfmann et al., 2022; Suryawanshi et al., 2022) . Overall, the 326 findings here of high-level protection in the lungs recapitulate observations in mRNA-1273-327 vaccinated humans of reduced disease severity following infection with Omicron (Abdullah et 328 al., 2021; Sigal, 2022; Wolter et al., 2022) . 329 330 Neutralizing antibodies to Omicron in the blood or ACE2 binding inhibitory antibodies in the 331 airway mucosa were low after the first 2 doses of mRNA-1273 at weeks 6-8 and low to 332 undetectable ~9 months later. Importantly, either mRNA-1273 or mRNA-Omicron boosts were 333 able to significantly increase neutralizing antibody titers against Omicron and Beta beyond their 334 initial peak consistent with a rapid recall B cell response. This also implies that neutralizing 335 antibody titers at extended times after vaccination may not be a reliable surrogate either for 336 vaccine efficacy in the lower airway or for predicting responses following a boost or infection as 337 they may not reflect the recall capacity of the underlying memory B cell population. 338

The observation that boosting with either mRNA-1273 or mRNA-Omicron resulted in the 340 expansion of a similarly high frequency of cross-reactive B cells likely stems from the principle 341 of original antigenic sin, otherwise termed antigenic imprinting, whereby prior immune memory 342 is recalled by a related antigenic encounter (Davenport and Hennessy, 1957; Davenport et al., 343 1953) . Recall of prior immunity may be either deleterious or beneficial as exemplified by the 344 impact of the circulating influenza A subtypes at the time of an individual's first exposure after 345 birth on patterns of disease susceptibility to subsequent pandemic influenza A outbreaks (Gostic 346 et al., 2016; Worobey et al., 2014) . The current worldwide distribution and evolution of SARS-347

CoV-2, however, is quite different from that of influenza A. Whereas multiple subtypes of Looking to the future, however, if Omicron, or a closely antigenically related variant, remains 362 the dominant circulating variant for some years to come, then it is possible that a change in the 363 initial vaccine regimen would be warranted, particularly in immunologically naïve populations 364 such as children as they reach the age of eligibility for approved COVID-19 vaccines. 365

Importantly, it would need to be established that a switch in COVID-19 vaccine design to match 366 the current dominant variant would not jeopardize responses against variants which may be 367 antigenically distant from Omicron but close to the prototype. Indeed a recent study has shown 368 that immunization of mice with an Omicron mRNA vaccine elicited strong neutralization against 369

Omicron but not to other variants, consistent with data from primary Omicron infection (Lee et 370 al., 2022; Roessler et al., 2022; Suryawanshi et al., 2022) . Thus, a combination or bivalent 371 vaccine to generate B cells specific for the current variant as well as cross-reactive to other 372 variants might ensure greater breadth of neutralization. 373

In summary, our findings highlight two important factors that will impact management of this 375 pandemic. The first is the design of the vaccine and whether it should be changed based on the 376 currently circulating variant. At present, boosting with mRNA-1273 provides robust increases in 377

neutralizing antibodies and appears to be sufficient to prevent severe disease after exposure from 378 all known variants (Baden et al., 2021a; Bruxvoort et al., 2021a; Bruxvoort et al., 2021b; 379 Chemaitelly et al., 2021; Corbett et al., 2020; Corbett et al., 2021c; Gagne et al., 2022; Pilishvili 380 et al., 2021; Tang et al., 2021) . Variant-matched vaccines may be preferable in the future if new 381 variants were to emerge that were even further antigenically distant such that cross-reactive 382 epitopes are rendered ineffective or if there were differences in the durability of neutralizing advantage is due to immune escape, the role of viral replication kinetics cannot be ruled out. 395

Here, viral titers were low in the lungs and low to undetectable in the upper airway. Second, 396 neutralizing antibody titers in NHP are 5-to 10-fold greater than in humans that received the 397 same dose and regimen of mRNA-1273 with a boost (Edara et al., 2021a; Pajon et al., 2022) . 398

Omicron. Finally, since we sought to compare two different mRNA boosts, we did not have an 400 unboosted group to determine whether the boost enhanced protection. As all the boosted NHP 401 were completely protected in the lungs, we were unable to determine an immune threshold for 402 protection. 403 404

406

Further information and requests for resources should be directed to and will be fulfilled by the 408 lead contact, Robert A. Seder (rseder@mail.nih.gov). 409 410

This study did not generate new unique reagents. 412 413 Data and code availability 414

• All data reported in this paper will be shared by the lead contact upon request. 415

• This paper does not report original code. 416

• Any additional information required to reanalyze the data reported in this paper is 417 available from the lead contact upon request. 418 419 Experimental model and subject details 420

A sequence-optimized mRNA encoding prefusion-stabilized SARS-CoV-2 S protein containing 422 2 proline stabilization mutations (S-2P) (Pallesen et al., 2017; Wrapp et al., 2020) 

Omicron were synthesized in vitro and formulated (Hassett et al., 2019) . Control mRNA 424 "UNFIX-01 (Untranslated Factor 9)" was synthesized and similarly formulated into lipid 425 nanoparticles as previously described (Corbett et al., 2021a) . live virus neutralization assays were previously described (Edara et al., 2021b; Edara et al., 445 2021c; Vanderheiden et al., 2020) . Viruses were propagated in Vero-TMPRSS2 cells to generate 446 viral stocks. Viral titers were determined by focus-forming assay on VeroE6-TMPRSS2 cells. 447 Viral stocks were stored at -80°C until use. 448 449

We used NEBNext Ultra II RNA Prep reagents and multiplex oligos (New England Biolabs) to 451

prepare Illumina-ready libraries, which were sequenced on a MiSeq (Illumina) as described 452

previously (Corbett et al., 2021c; Gagne et al., 2022) . Demultiplexed sequence reads were 453 analyzed in the CLC Genomics Workbench v.21.0.3 by (1) trimming for quality, length, and 454 adaptor sequence, (2) mapping to the Wuhan-Hu-1 SARS-CoV-2 reference (GenBank no. 455

deletions (indels), and (4) generating both a sample consensus sequence and a list of variants. 457

Default settings were used for all tools. 458 459

Macaques were challenged at week 45 (4 weeks after the second boost) with a total dose of 1 × 461 10 6 PFU of SARS-CoV-2 Omicron. The viral inoculum was administered as 7.5 ×10 5 PFUs in 462 3mL intratracheally and 2.5 ×10 5 PFUs in 1mL intranasally in a volume of 0.5mL distributed 463 evenly into each nostril. 464 465

Quantification of antibodies in the blood and mucosa were performed as previously described 467 (Corbett et al., 2020) . Briefly, total IgG antigen-specific antibodies to variant SARS-CoV-2 S-468 and RBD-derived antigens were determined in a multiplex serology assay by MSD V-Plex 469 SARS-CoV-2 Panel 23 for S and MSD V-Plex SARS-CoV-2 Panel 22 for RBD) according to 470 manufacturer's instructions, except 25μl of sample and detection antibody were used per well. 471

Heat inactivated plasma was initially diluted 1:100 and then serially diluted 1:10 for blood S-472 and 1:4 for RBD-binding. BAL fluid and nasal washes were concentrated 10-fold with Amicon 473 Ultra centrifugal filter devices (Millipore Sigma). Concentrated samples were diluted 1:5 prior to 474 5-fold serial dilutions. 475

While S antigens were used for binding ELISAs, S-2P antigens were used for ACE2 inhibition 478 assays and B cell probe binding. S-2P constructs were made as follows. Biotinylated S probes 479 were expressed transiently for WA1, Delta, Beta and Omicron strains and purified and 480 biotinylated in a single in-process step (Teng et al., 2021; Zhou et al., 2020) . S-2P for WA1 and 481

Omicron were made as previously described (Olia et al., 2021) . FRNT assays were performed as previously described (Edara et al., 2021b; Edara et al., 2021c; 498 Vanderheiden et al., 2020) . Briefly, samples were diluted at 3-fold in 8 serial dilutions using 499 DMEM (VWR, #45000-304) in duplicates with an initial dilution of 1:10 in a total volume of 500 60µl. Serially diluted samples were incubated with an equal volume of WA1, Delta, Beta or 501

Omicron (100-200 foci per well based on the target cell) at 37 o C for 45 minutes in a round-502 bottomed 96-well culture plate. The antibody-virus mixture was then added to VeroE6-503 TMPRSS2 cells and incubated at 37 o C for 1 hour. Post-incubation, the antibody-virus mixture 504 was removed and 100µl of pre-warmed 0.85% methylcellulose overlay was added to each well. 505

Plates were incubated at 37 o C for 18 hours and the methylcellulose overlay was removed and 506 washed six times with PBS. Cells were fixed with 2% paraformaldehyde in PBS for 30 minutes. 507

Following fixation, plates were washed twice with PBS and permeabilization buffer (0.1% BSA, 508 0.1% Saponin in PBS) was added to permeabilized cells for at least 20 minutes. Cells were 509 incubated with an anti-SARS-CoV S primary antibody directly conjugated to Alexaflour-647 510 (CR3022-AF647) overnight at 4°C. Foci were visualized and imaged on an ELISPOT reader 511 (CTL). Antibody neutralization was quantified by counting the number of foci for each sample 512 using the Viridot program (Katzelnick et al., 2018) . The neutralization titers were calculated as 513 follows: 1 -(ratio of the mean number of foci in the presence of sera and foci at the highest 514 dilution of respective sera sample). Each specimen was tested in duplicate. The FRNT-50 titers 515 were interpolated using a 4-parameter nonlinear regression in GraphPad Prism 9.2.0. Samples 516 that do not neutralize at the limit of detection (LOD) at 50% are plotted at 20 and was used for 517 geometric mean and fold-change calculations. The assay LOD was 20. Farzan and Huihui Mu at Scripps) as previously described (Gilbert et al., 2021; Shen et al., 525 2021) . SARS-CoV-2 S-pseudotyped virus was prepared by transfection in 293T/17 cells (human 526 embryonic kidney cells in origin; obtained from American Type Culture Collection, #CRL-527 11268) using a lentivirus backbone vector, a spike-expression plasmid encoding S protein from 528

Wuhan-Hu-1 strain (GenBank no. NC_045512) with a p.Asp614Gly mutation, a TMPRSS2 529 expression plasmid and a firefly Luc reporter plasmid. For pseudovirus encoding the S from 530

Delta, Beta and Omicron, the plasmid was altered via site-directed mutagenesis to match the S 531 sequence to the corresponding variant sequence as previously described (Corbett et al., 2021a) . A 532 pre-titrated dose of pseudovirus was incubated with eight serial 5-fold dilutions of serum 533 samples (1:20 start dilution) in duplicate in 384-well flat-bottom tissue culture plates (Thermo 534

Fisher, #12-565-344) for 1 hour at 37ºC prior to adding 293T/ACE2 cells. One set of 14 wells 535 received cells and virus (virus control) and another set of 14 wells received cells only 536 (background control), corresponding to technical replicates. Luminescence was measured after 537 66-72 hours of incubation using Britelite-Plus luciferase reagent (Perkin Elmer, #6066769). 538

Neutralization titers are the inhibitory dilution of serum samples at which relative luminescence 539 units (RLUs) were reduced by 50% (ID50) compared to virus control wells after subtraction of 540 background RLUs. Serum samples were heat-inactivated for 30-45 minutes at 56ºC prior to 541 assay. 542 543 Serum antibody avidity 544 Avidity was measured as described previously (Francica et al., 2021) in an adapted ELISA assay. 545

Briefly, ELISA against S-2P was performed in the absence or presence of sodium thiocyanate 546 (NaSCN) and developed with HRP-conjugated goat anti-monkey IgG (H+L) secondary antibody 547 (Invitrogen) and SureBlue 3,3′,5,5′-tetramethylbenzidine (TMB) microwell peroxidase substrate 548

(1-Component; SeraCare) and quenched with 1 N H2SO4. The avidity index (AI) was calculated 549 as the ratio of IgG binding to S-2P in the absence or presence of NaSCN. 550 551

Serum epitope mapping competition assays were performed, as previously described (Corbett et 553 al., 2021a) , using the Biacore 8K+ surface plasmon resonance system (Cytiva). Briefly, through 554 primary amine coupling using a His capture kit (Cytiva), anti-histidine antibody was 555 immobilized on Series S Sensor Chip CM5 (Cytiva) allowing for the capture of his-tagged 556 SARS-CoV-2 S-2P on active sensor surface. 557 558 Human IgG monoclonal antibodies (mAbs) used for these analyses include: RBD-specific mAbs 559 B1-182, A19-46.1, A20-29.1, A19-61.1, S309, A23-97.1 and A23-80.1. Negative control 560 antibody or competitor mAb was injected over both active and reference surfaces. Following 561 this, NHP sera (diluted 1:50) was flowed over both active and reference sensor surfaces. Active 562 and reference sensor surfaces were regenerated between each analysis cycle. 563 564 For analysis, sensorgrams were aligned to Y (Response Units) = 0, using Biacore 8K Insights 565

Evaluation Software (Cytiva) beginning at the serum association phase. Relative "analyte 566 binding late" report points (RU) were collected and used to calculate fractional competition (% 567 C) using the following formula: % C = [1 -(100 * ( (RU in presence of competitor mAb) / (RU 568 in presence of negative control mAb) ))]. Results are reported as fractional competition. Assays 569 were performed in duplicate, with average data point represented on corresponding graphs. 570 571 B cell probe binding 572

Kinetics of S-specific memory B cells responses were determined as previously described 573 (Gagne et al., 2022) . Briefly, cryopreserved PBMC were thawed and stained with the following or Omicron S-2P and streptavidin-BUV661 (BD Biosciences) labeled WA1 or Delta S-2P for 30 584 minutes at 4°C (protected from light). Cells were washed and fixed in 0.5% formaldehyde 585 (Tousimis Research Corp) prior to data acquisition. Aqua live/dead fixable dead cell stain kit 586 (Thermo Fisher Scientific) was used to exclude dead cells. All antibodies were previously 587 titrated to determine the optimal concentration. Samples were acquired on an BD FACSymphony 588 cytometer and analyzed using FlowJo version 10.7.2 (BD, Ashland, OR). 589 590

Intracellular cytokine staining was performed as previously described (Donaldson et al., 2019; 592 Gagne et al., 2022) . Briefly, cryopreserved PBMC and BAL cells were thawed and rested 593 overnight in a 37°C/5% CO2 incubator. The following morning, cells were stimulated with 594 SARS-CoV-2 S protein (S1 and S2, matched to vaccine insert) peptide pools (JPT Peptides) at a 595 final concentration of 2 μg/ml in the presence of 3mM monensin for 6 hours. The S1 and S2 sgRNA was isolated and quantified by researchers blinded to vaccine history as previously 615 described (Corbett et al., 2021c) , except for the use of a new probe noted below. Briefly, total 616 RNA was extracted from BAL fluid and nasal swabs using RNAzol BD column kit (Molecular 617

Research Center). PCR reactions were conducted with TaqMan TCID50 was quantified as previously described (Corbett et al., 2021c) . Briefly, Vero-TMPRSS2 632 cells were plated and incubated overnight. The following day, BAL samples were serially 633 diluted, and the plates were incubated at 37 °C/5.0% CO2 for four days. Positive (virus stock of 634 known infectious titer in the assay) and negative (medium only) control wells were included in 635 each assay setup. The cell monolayers were visually inspected for cytopathic effect. TCID50 636 values were calculated using the Reed-Muench formula. 637 638

Routine histopathology and detection of SARS-CoV-2 virus antigen via immunohistochemistry 640 (IHC) were performed as previously described (Corbett et al., 2020; Gagne et al., 2022) . Briefly, 641 seven to nine days following Omicron challenge animals were euthanized and lung tissue was See also Figure S1 for experimental schema and Table S1 for detailed neutralizing titers. See also Table S2 for list of mutations in variant-specific S-2P-ACE2 inhibition assays. See also Figure S7 for Omicron challenge stock sequence. (B) SARS-CoV-2 antigen and inflammation scores in the left cranial lobe (Lc), right middle lobe (Rmid) and right caudal lobe (Rc) of the lungs. Antigen scoring legend: -no antigen detected; +/rare to occasional foci; + occasional to multiple foci; ++ multiple to numerous foci; +++ numerous foci. Inflammation scoring legend: -minimal to absent inflammation; +/-minimal to mild inflammation; + mild to moderate inflammation; ++ moderate to severe inflammation; +++ severe inflammation. Horizontal rows correspond to individual NHP depicted above (A).

Decreased severity of disease during the 705 first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa

Association Between 3 Doses of mRNA COVID-19 Vaccine 709 and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Effectiveness of COVID-19 booster vaccines against covid-19 related symptoms, 712 hospitalisation and death in England

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. 715

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 718 Vaccine

Protection against Covid-19 by BNT162b2 Booster across Age 721 Groups

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for 724 preventing severe outcomes in Israel: an observational study

SARS-CoV-2 Omicron-B.1.1.529 Variant leads to 727 less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-728 19. bioRxiv

Covid-19 Breakthrough Infections in Vaccinated 731 Health Care Workers

Effectiveness of mRNA-1273 against delta, mu, and other 734 emerging variants of SARS-CoV-2: test negative case-control study

Real-world effectiveness of the mRNA-1273 vaccine against 737 COVID-19: Interim results from a prospective observational cohort study

Omicron extensively but incompletely escapes Pfizer 741 BNT162b2 neutralization

mRNA-1273 COVID-19 vaccine 744 effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in 748 healthy adults: an interim analysis

Evaluation of the mRNA-1273 Vaccine against 751 SARS-CoV-2 in Nonhuman Primates

Protection against SARS-CoV-2 beta variant in 754 mRNA-1273 vaccine-boosted nonhuman primates

Immune correlates of protection by mRNA-1273 vaccine 757 against SARS-CoV-2 in nonhuman primates

mRNA-1273 protects against SARS-CoV-2 beta infection in 760 nonhuman primates

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass 763 Vaccination Setting

Predetermination by infection and by vaccination 765 of antibody response to influenza virus vaccines

Epidemiologic and immunologic 767 significance of age distribution of antibody to antigenic variants of influenza virus

Outcomes of

CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the 772 Western Cape Province, South Africa. medRxiv

OMIP-052: An 18-Color Panel for 774

Measuring Th1, Th2, Th17, and Tfh Responses in Rhesus Macaques

mRNA-1273 and BNT162b2 mRNA vaccines have 777 reduced neutralizing activity against the SARS-CoV-2 Omicron variant. bioRxiv

Infection-and vaccine-induced 781 antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Infection and Vaccine-Induced Neutralizing-785

Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Protective antibodies elicited by SARS-CoV-2 spike 788 protein vaccination are boosted in the lung after challenge in nonhuman primates

Evolution of antibody immunity to SARS-792 CoV-2

CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with 796 anamnestic antibody response in the lung

mRNA-based COVID-19 vaccine 799 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Immune correlates analysis of the 802 mRNA-1273 COVID-19 vaccine efficacy clinical trial

Waning Immunity after the BNT162b2 Vaccine 805 in Israel

Potent protection 807 against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting

The Spread of SARS-CoV-2 Variant 810 Omicron with a Doubling Time of 2.0-3.3 Days Can Be Explained by Immune Evasion

SARS-CoV-2 Omicron virus causes attenuated 814 disease in mice and hamsters

Vaccine effectiveness against 817 SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster 818 BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv

Optimization of Lipid Nanoparticles for 822 Intramuscular Administration of mRNA Vaccines

The Omicron variant is highly 825 resistant against antibody-mediated neutralization: Implications for control of the COVID-19 826 pandemic

An mRNA Vaccine 829 against SARS-CoV-2 -Preliminary Report

Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular 832 helper cell differentiation

Viridot: An automated virus 835 plaque (immunofocus) counter for the measurement of serological neutralizing responses with 836 application to dengue virus

Omicron infection of vaccinated individuals enhances neutralizing 839 immunity against the Delta variant. medRxiv

The Architecture of 841 SARS-CoV-2 Transcriptome

Omicron-specific mRNA vaccine induced potent neutralizing 844 antibody against Omicron but not other SARS-CoV-2 variants. bioRxiv

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19

Omicron Wave Compared With Previous Waves

SARS-CoV-2 Omicron spike mediated immune 850 escape, infectivity and cell-cell fusion. bioRxiv

Neutralization of SARS-CoV-2 Omicron by BNT162b2 853 mRNA vaccine-elicited human sera

Bcl6 mediates the development of T follicular helper cells

SARS-CoV-2 S2P spike ages through distinct states with altered 859 immunogenicity

SARS-CoV-2 Omicron Variant Neutralization after mRNA-862

Booster Vaccination

Immunogenicity and structures of a rationally 865 designed prefusion MERS-CoV spike antigen

Effectiveness of mRNA Covid-19 868 Vaccine among U.S. Health Care Personnel

Reduced sensitivity of SARS-CoV-2 variant 871 Delta to antibody neutralization

Safety and Efficacy of the BNT162b2 mRNA 874 Covid-19 Vaccine

Neutralization profile of Omicron 876 variant convalescent individuals. medRxiv

Plasma Neutralization of the SARS-CoV-2 Omicron 879 Variant

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies 882 elicited by ancestral spike vaccines

Milder disease with Omicron: is it the virus or the pre-existing immunity?

Limited cross-variant immunity after 887 infection with the SARS-CoV-2 Omicron variant without vaccination. medRxiv

COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Isotype switching by 893 human B cells is division-associated and regulated by cytokines

Molecular probes of spike ectodomain and its 896 subdomains for SARS-CoV-2 variants, Alpha through Omicron. bioRxiv

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and 899 delta variants. medRxiv

Development of a Rapid Focus 902

Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

Rapid epidemic expansion of the SARS-CoV-2 Omicron 906 variant in southern Africa

Ultrapotent antibodies against diverse and highly transmissible 909 SARS-CoV-2 variants

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms 912 and the ability to use ACE2 receptors from additional species

The hyper-transmissible SARS-CoV-2 Omicron variant 915 exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. 916 medRxiv

Early assessment of the clinical severity of the 919 SARS-CoV-2 omicron variant in South Africa: a data linkage study

Genesis and pathogenesis of the 1918 921 pandemic H1N1 influenza A virus

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure-Based Design with Tag-Based Purification and

Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

Memory B cell specificities following immunization and boosting (A-D) Representative flow cytometry plots showing single variant-specific (top left and bottom right quadrant) and dual-variant specific (top right quadrant) memory B cells at weeks 0

Event frequencies per gate are expressed as a percentage of all classswitched memory B cells. Cross-reactivity shown for (A)